Deepverge

Deepverge is a vertically integrated business that collaborates with partners in artificial intelligence, clinical research, water technologies, medical devices, and life sciences. The company's flagship product, Labskin, serves as an AI backbone for its collaborators, allowing skin-care, health-care, pharmaceutical manufacturers, and cosmetic companies to test their products on human-like skin in a real-world environment. This innovative approach provides full access to multiple state-of-the-art partner technologies. Since its foundation in 2016, Deepverge has made significant strides in the Health Care industry, with its headquarters in the United Kingdom. The company recently secured a £4.00MPost-IPO Debt investment on 19 March 2022, demonstrating confidence from investors such as Riverfort Global Opportunities PLC and YA II PN. The investment signifies growing interest in Deepverge's collaborative approach, potentially positioning the company for further expansion and technological advancement within the health and science sectors.